CJC-1295 Side Effects: Safety Profile, Risks & What to Expect (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Side Effects
Clinical trials reported that CJC-1295 was generally well-tolerated, with no serious adverse reactions at therapeutic doses.
Common Side Effects:
Injection site reactions (redness, pain, swelling)
Flushing and warmth, particularly facial flushing lasting 5–10 minutes post-injection
Water retention
Headaches
Dizziness
Increased hunger
Tingling or numbness in extremities
Fatigue or lethargy initially
Less Common Side Effects:
Nausea
Joint discomfort
Mood changes
Anxiety
Flu-like symptoms
Potential Concerns: The FDA has noted concerns about increased heart rate and cardiac events associated with CJC-1295. Individuals with active cancer, cardiovascular disease, or diabetes should exercise caution, as elevated GH and IGF-1 can theoretically promote cell proliferation and affect glucose metabolism.
Frequently Asked Questions
Many users employ CJC-1295 for its potential anti-aging benefits, as elevated GH and IGF-1 levels are associated with improved skin quality, body composition, and recovery. However, long-term safety data for this application is limited.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
Aidsmap. Lipodystrophy study halted after patient death. 2006.
World Anti-Doping Agency. The 2024 Prohibited List International Standard.
FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
Hone Health. Everything You Need to Know About the FDA Peptide Ban.
Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.